chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 1.4
Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Adenoidectomy, Asthma, Autism, Bronchial hyperreactivity, Cognitive disorder
Clinical narrative: Follow-up information was received that provided patient gender, suspect vaccines, additional events and laboratory test results. This case was considered medically important. Medical records regarding Hib were received from an attorney regarding a male patient received the fourth dose on 25-Oct-2000 along with the third dose of IPOL (manufacturer unknown) and the fourth dose of DTaP (manufacturer unknown) at the age of 17 months and experienced encephalopathy, pervasive developmental disorder NOS, autism, neurodevelopmental disorder, pica, delayed language and mercury poisoning. On 25-Oct-2000, the patient received the fourth dose of Hib along with other childhood vaccines. The child received vaccines from birth up to 18 months of age, age allegedly  experienced mercury poisoning as a  result of the cumulative exposure to mercury in the vaccines. On an unspecified date, the patient experienced autism, neurodevelopmental disorder, pica, and delayed language. In Nov-2001, the child was diagnosed with encephalopathy. In Jan-2002, the patient was diagnosed with pervasive developmental disorder NOS. It was unknown if the patient recovered from the events. DNA test fragile X (results: negative) was done on 06-Feb-2002. Blood lead (results: 5 ug/dL) was done in 24-Feb-2003. No additional information was available at the time of this report.
Age: 1.4
Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Cough, Developmental delay, Disturbance in social behaviour, Feeding disorder, Gastrooesophageal reflux disease
Clinical narrative: Follow-up information was received that provided patient gender, suspect vaccines, additional events and laboratory test results. This case was considered medically important. Medical records regarding Hib were received from an attorney regarding a male patient received the fourth dose on 25-Oct-2000 along with the third dose of IPOL (manufacturer unknown) and the fourth dose of DTaP (manufacturer unknown) at the age of 17 months and experienced encephalopathy, pervasive developmental disorder NOS, autism, neurodevelopmental disorder, pica, delayed language and mercury poisoning. On 25-Oct-2000, the patient received the fourth dose of Hib along with other childhood vaccines. The child received vaccines from birth up to 18 months of age, age allegedly  experienced mercury poisoning as a  result of the cumulative exposure to mercury in the vaccines. On an unspecified date, the patient experienced autism, neurodevelopmental disorder, pica, and delayed language. In Nov-2001, the child was diagnosed with encephalopathy. In Jan-2002, the patient was diagnosed with pervasive developmental disorder NOS. It was unknown if the patient recovered from the events. DNA test fragile X (results: negative) was done on 06-Feb-2002. Blood lead (results: 5 ug/dL) was done in 24-Feb-2003. No additional information was available at the time of this report.
Age: 1.4
Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Hypokinesia, Mental impairment, Metal poisoning, Nasal congestion, Nervous system disorder
Clinical narrative: Follow-up information was received that provided patient gender, suspect vaccines, additional events and laboratory test results. This case was considered medically important. Medical records regarding Hib were received from an attorney regarding a male patient received the fourth dose on 25-Oct-2000 along with the third dose of IPOL (manufacturer unknown) and the fourth dose of DTaP (manufacturer unknown) at the age of 17 months and experienced encephalopathy, pervasive developmental disorder NOS, autism, neurodevelopmental disorder, pica, delayed language and mercury poisoning. On 25-Oct-2000, the patient received the fourth dose of Hib along with other childhood vaccines. The child received vaccines from birth up to 18 months of age, age allegedly  experienced mercury poisoning as a  result of the cumulative exposure to mercury in the vaccines. On an unspecified date, the patient experienced autism, neurodevelopmental disorder, pica, and delayed language. In Nov-2001, the child was diagnosed with encephalopathy. In Jan-2002, the patient was diagnosed with pervasive developmental disorder NOS. It was unknown if the patient recovered from the events. DNA test fragile X (results: negative) was done on 06-Feb-2002. Blood lead (results: 5 ug/dL) was done in 24-Feb-2003. No additional information was available at the time of this report.
Age: 1.4
Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Regressive behaviour, Repetitive speech, Sleep apnoea syndrome, Social avoidant behaviour, Speech disorder
Clinical narrative: Follow-up information was received that provided patient gender, suspect vaccines, additional events and laboratory test results. This case was considered medically important. Medical records regarding Hib were received from an attorney regarding a male patient received the fourth dose on 25-Oct-2000 along with the third dose of IPOL (manufacturer unknown) and the fourth dose of DTaP (manufacturer unknown) at the age of 17 months and experienced encephalopathy, pervasive developmental disorder NOS, autism, neurodevelopmental disorder, pica, delayed language and mercury poisoning. On 25-Oct-2000, the patient received the fourth dose of Hib along with other childhood vaccines. The child received vaccines from birth up to 18 months of age, age allegedly  experienced mercury poisoning as a  result of the cumulative exposure to mercury in the vaccines. On an unspecified date, the patient experienced autism, neurodevelopmental disorder, pica, and delayed language. In Nov-2001, the child was diagnosed with encephalopathy. In Jan-2002, the patient was diagnosed with pervasive developmental disorder NOS. It was unknown if the patient recovered from the events. DNA test fragile X (results: negative) was done on 06-Feb-2002. Blood lead (results: 5 ug/dL) was done in 24-Feb-2003. No additional information was available at the time of this report.
Age: 1.4
Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Speech disorder developmental, Stereotypy, Unresponsive to stimuli, Vomiting
Clinical narrative: Follow-up information was received that provided patient gender, suspect vaccines, additional events and laboratory test results. This case was considered medically important. Medical records regarding Hib were received from an attorney regarding a male patient received the fourth dose on 25-Oct-2000 along with the third dose of IPOL (manufacturer unknown) and the fourth dose of DTaP (manufacturer unknown) at the age of 17 months and experienced encephalopathy, pervasive developmental disorder NOS, autism, neurodevelopmental disorder, pica, delayed language and mercury poisoning. On 25-Oct-2000, the patient received the fourth dose of Hib along with other childhood vaccines. The child received vaccines from birth up to 18 months of age, age allegedly  experienced mercury poisoning as a  result of the cumulative exposure to mercury in the vaccines. On an unspecified date, the patient experienced autism, neurodevelopmental disorder, pica, and delayed language. In Nov-2001, the child was diagnosed with encephalopathy. In Jan-2002, the patient was diagnosed with pervasive developmental disorder NOS. It was unknown if the patient recovered from the events. DNA test fragile X (results: negative) was done on 06-Feb-2002. Blood lead (results: 5 ug/dL) was done in 24-Feb-2003. No additional information was available at the time of this report.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Autism, Autism spectrum disorder, Blood lead normal, Metal poisoning, Nervous system disorder
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Speech disorder developmental
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Abnormal behaviour, Antisocial behaviour, Aphasia, Autism, Autism spectrum disorder
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Biopsy, Central venous catheter removal, Central venous catheterisation, Chelation therapy, Corneal abrasion
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Duodenitis, Ear infection, Ear tube insertion, Gastrooesophageal reflux disease, Gluten free diet
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Inappropriate schedule of drug administration, Myringotomy, Sinusitis, Speech disorder, Stool analysis
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Viral infection
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Abnormal behaviour, Autism, Autism spectrum disorder, Biopsy, Biopsy intestine abnormal
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Corneal abrasion, Duodenitis, Ear infection, Ear tube insertion, Gastrooesophageal reflux disease
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Gluten free diet, Myringotomy, Neurological examination abnormal, Sinusitis, Speech disorder
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Sex: M
Vaccine: DTAP, HEP, HIBV, MMR, VARCEL, HEP, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Stool analysis, Urine analysis, Viral infection
Clinical narrative: Follow-up information provided additional events, product details, lab results and patient demographics. This case was considered medically important. Information regarding Hib-Titer Vaccine was received from an attorney regarding an 18-month-old male patient who experienced PDD, autism, speech language delay, neurological damage and mercury poisoning. The patient received the fourth dose on 11-Oct-2000. The patient also received the fourth dose of DTaP (manufacturer unknown) on 11-Oct-2000. Medical records received from an attorney, alleged that on unspecified dates, the patient having received a dose of Hib, along with other childhood vaccines, experienced PDD in Jan-2001, autism in Feb-2001 and speech language delay in Oct--2001. The patient also experienced neurological damage and mercury poisoning. The patient's outcome was unknown. No additional information was available at the time of this report. Blood lead (results: 5 ug/dL) was done on 26-Dec-2000.
Age: 0.2
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Autopsy, Pyrexia
Clinical narrative: Immunizations given 3/22/07 approx 8:30am mom reported mild fever at MN 3/23/07 - gave infant Tylenol drops. Found infant dead in crib 3/23/07 at 7:30AM!  7/3/07 Received Autopsy Report which reveals COD as Undetermined & manner of Death as Undetermined.  Final anatomic diagnoses were: clean & apparently well care for; no evidence of trauma or injury; lung & thymus petechiae; and focal mild acute bronchopneumonia of right lung.
Age: 0.22
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Ultrasound scan
Clinical narrative: Intussusception 4/13/07 Received hospital d/c summary & vax record from PCP/reporter which reveals patient admitted overnight 3/27-3/28/07 s/p air contrast enema reduction of ileal colonic IS. Unable to reduce initially & patient had gen anesthesia.  That relaxation allowed reduction.. FINAL DX: Ileal colonic IS, reduced by air contrast enema under gen anesthesia.
Age: 0.22
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Ascites, Intubation, Intussusception, Large intestinal obstruction reduction, Sedation
Clinical narrative: Intussusception 4/13/07 Received hospital d/c summary & vax record from PCP/reporter which reveals patient admitted overnight 3/27-3/28/07 s/p air contrast enema reduction of ileal colonic IS. Unable to reduce initially & patient had gen anesthesia.  That relaxation allowed reduction.. FINAL DX: Ileal colonic IS, reduced by air contrast enema under gen anesthesia.
Age: 0.22
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Small intestinal intussusception reduction, Ultrasound abdomen abnormal
Clinical narrative: Intussusception 4/13/07 Received hospital d/c summary & vax record from PCP/reporter which reveals patient admitted overnight 3/27-3/28/07 s/p air contrast enema reduction of ileal colonic IS. Unable to reduce initially & patient had gen anesthesia.  That relaxation allowed reduction.. FINAL DX: Ileal colonic IS, reduced by air contrast enema under gen anesthesia.
Age: 0.22
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Ascites, Barium double contrast, Intubation, Intussusception, Sedation
Clinical narrative: Intussusception 4/13/07 Received hospital d/c summary & vax record from PCP/reporter which reveals patient admitted overnight 3/27-3/28/07 s/p air contrast enema reduction of ileal colonic IS. Unable to reduce initially & patient had gen anesthesia.  That relaxation allowed reduction.. FINAL DX: Ileal colonic IS, reduced by air contrast enema under gen anesthesia.
Age: 0.22
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Ultrasound scan abnormal
Clinical narrative: Intussusception 4/13/07 Received hospital d/c summary & vax record from PCP/reporter which reveals patient admitted overnight 3/27-3/28/07 s/p air contrast enema reduction of ileal colonic IS. Unable to reduce initially & patient had gen anesthesia.  That relaxation allowed reduction.. FINAL DX: Ileal colonic IS, reduced by air contrast enema under gen anesthesia.
Age: 23.0
Sex: F
Vaccine: HPV4
Symptoms: Abortion spontaneous, Drug exposure during pregnancy, Gynaecological examination, Laboratory test, Ultrasound scan
Clinical narrative: Information has been received from a consumer and a licensed practical nurse, through the pregnancy registry, concerning a 23 year old female, who was vaccinated on 28-SEP-2006 with the first dose of Gardasil, and on 28-NOV-2006 with the second dose of Gardasil (Lot # 653735/0688F). There was no concomitant medication. The nurse reported that on 26-FEB-2007 (consumer reported as 13-MAR-2007, "some time after"she received the second dose) the patient had a miscarriage. The date of the last LMP was approximately 31-JAN-2007 ("late January"). According to the consumer, lab diagnostic tests included "several blood tests, ultrasounds, vaginal probe" (results not provided). On 29-MAR-2007, the third dose of Gardasil (Lot # 654389/0961F) was administered to the patient, and the nurse reported the patient "was fine" at that visit. The miscarriage was considered to be an other important medical event. Additional information has been requested.
Age: 0.35
Sex: U
Vaccine: RV5
Symptoms: Haematochezia
Clinical narrative: Information has been received from a physician concerning an 18-week-old patient who on 22-FEB-2007 was vaccinated PO with the second 2.0 ml dose of Rotateq (Lot #656103/1166F) (1st dose administrated on 08-DEC-2006). The physician reported that on 23-FEB-2007, the patient developed bloody stool. The patient was taken to the Emergency Room (ER) and was discharged with a negative outcome. The patient subsequently recovered. Upon internal review, bloody stool was determined to be an other important medical event. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Dyspnoea, Hypersensitivity, Lethargy, Rash
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Chills, Cough, Dyspnoea, Flushing, Hypersensitivity
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Hypotension, Injection site urticaria, Lethargy, Rash, Sneezing
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Urticaria
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Chills, Cough, Flushing, Injection site urticaria, Sneezing
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 4.0
Sex: F
Vaccine: VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL, DTAP, IPV, MMR, VARCEL
Symptoms: Flushing, Injection site urticaria, Pruritus, Syncope
Clinical narrative: Information has been received from a physician concerning a 4-year-old female who on 26-MAR-2007 was vaccinated with a 0.5 ml booster dose of Varivax. On 26-MAR-2007, following vaccination, the patient experienced a severe allergic reaction, a rash, became very lethargic and had breathing problems. Unspecified medical attention was sought and the patient was given BENADRYL and symptoms resolved. No product quality complaint was involved. The physician considered the patient's reactions to be life threatening. Additional information has been requested.
Age: 42.0
Sex: F
Vaccine: TDAP
Symptoms: Cellulitis, Headache, Injection site erythema, Injection site pain, Injection site warmth
Clinical narrative: After receiving Tdap patient experienced redness at site and headache.  While removing band-aid she scratched the scab off injection site with her nail and consequently developed redness, warmth, and tenderness at injection site.  Patient was treated for cellulitis with doxycycline 100mg PO BID for 10 days.  Will monitor injection site for increased signs and symptoms.
Age: 0.5
Sex: M
Vaccine: DTAP, HIBV, IPV, PNC
Symptoms: Chest X-ray, Pyrexia, Urine analysis, Vomiting
Clinical narrative: High fever up to 106.2 degrees rectally that occurred Saturday night, 04/07/2007,(about 2.5 days after vaccinations). Vomitted 1 time during 1st night after receiving vaccinations.  Took to ER on Saturday night when fever got so high.  ER docs did thorough exam, including chest film and U/A and found nothing wrong.  Sent home with instructions to give alternating Tylenol and Motrin.  Fever finally got down to 101 rectally after this regimen begun.  Fever did not completely go away until Monday morning at about 3:00.  No residual problems after this.
Age: 66.0
Sex: M
Vaccine: TD
Symptoms: Dermatitis allergic, Paraesthesia, Rash
Clinical narrative: Pt given Td on 3/26/07. Within the hour of administration, pt c/o breaking out along his trunk, back, under his arms, and above his waist.  Denied shortness of breath but states body feels tingly. Instructed pt to take Benadryl and has f/u on 3/27/07. Pt had been on Septra the previous week for infection and had been off of this med for 4-5 days prior to the reaction.  Diagnosed with Allergic dermatitis secondary to Td or Septra abx.
Age: 55.0
Sex: F
Vaccine: TDAP
Symptoms: Cellulitis, Influenza like illness, Injection site erythema, Injection site induration, Injection site swelling
Clinical narrative: Swelling/redness at injection site within hours of injection. Flulike symptoms with myalgias, malaise, more swelling/pain/redness, lymphadenopathy (axillary, supraclavicular) within 24 hours.  4 days postinjection:  10 x 7 cm induration, heat, redness at injection site.  Treatment with dicloxacillin 500mg qid for cellulitis.
Age: 55.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site warmth, Lymphadenopathy, Malaise, Myalgia, Pain
Clinical narrative: Swelling/redness at injection site within hours of injection. Flulike symptoms with myalgias, malaise, more swelling/pain/redness, lymphadenopathy (axillary, supraclavicular) within 24 hours.  4 days postinjection:  10 x 7 cm induration, heat, redness at injection site.  Treatment with dicloxacillin 500mg qid for cellulitis.
Age: 30.0
Sex: F
Vaccine: MNQ
Symptoms: Musculoskeletal stiffness, Neck pain, Pain in extremity
Clinical narrative: Received vaccine on Friday morning. Mild arm soreness that evening. On waking on Saturday morning, had moderate neck stiffness/soreness bilaterally. Took ibuprofen with some relief, but still had pain with neck movement. Neck soreness continues from ear to shoulder.
Age: 32.0
Sex: F
Vaccine: HEP
Symptoms: Abdominal pain upper, Bladder spasm, Burning sensation, Flushing, Hypersensitivity
Clinical narrative: On 4/2/07,appox 6 hours after subject given initial dose of Hep-B vaccine, she experienced facial/neck flushing & burning.  Also had rash to face, neck & chest.  Morning of 4/3/07 symptoms progressed with swelling in throat & tongue with difficulty in swallowing.  Additionally, experienced swelling, redness & rash in bilateral hands.  Symptoms continued to progress on 4/3/07 so subject took diphenhydramine and hydroxazine on that date.  On 4/4/07, subject returned to employee health and reported symptoms to us.  She was then sent to Ergent Care & seen by physician.  She additionally experienced bladder spasms & stomach pain. Was told by physician that she was having an allergic reaction to the Hep-B vaccine.  Was instructed to continue diphenhydramine and hydroxazine.  Was given steroid injection at Ergent Care, as well as given Medrol Dose-Pack.
Age: 32.0
Sex: F
Vaccine: HEP
Symptoms: Rash generalised
Clinical narrative: On 4/2/07,appox 6 hours after subject given initial dose of Hep-B vaccine, she experienced facial/neck flushing & burning.  Also had rash to face, neck & chest.  Morning of 4/3/07 symptoms progressed with swelling in throat & tongue with difficulty in swallowing.  Additionally, experienced swelling, redness & rash in bilateral hands.  Symptoms continued to progress on 4/3/07 so subject took diphenhydramine and hydroxazine on that date.  On 4/4/07, subject returned to employee health and reported symptoms to us.  She was then sent to Ergent Care & seen by physician.  She additionally experienced bladder spasms & stomach pain. Was told by physician that she was having an allergic reaction to the Hep-B vaccine.  Was instructed to continue diphenhydramine and hydroxazine.  Was given steroid injection at Ergent Care, as well as given Medrol Dose-Pack.
Age: 1.0
Sex: F
Vaccine: MMR, PNC, VARCEL
Symptoms: Vaccination failure, Varicella
Clinical narrative: Chickenpox.  Rash onset 4/7/07.
Age: 1.83
Sex: F
Vaccine: HEPA, VARCEL
Symptoms: Injection site rash
Clinical narrative: Mother called with complaint of a rash that appeared within 2 days after immunizations around the site of the immunizations.  The rash is approx 1 1/2- 2 inches around the injection site.  The rash has continued in same area but is not going away which is why the mother called.  She states it does not appear to be itchy and it is not a blister or pimple-like in appearance.
Age: 1.0
Sex: F
Vaccine: HIBV, MMRV
Symptoms: Skin lesion, Vaccination failure, Varicella
Clinical narrative: Patient came into the office today with Chicken Pox lesions on torso.  Onset was on 4/8/07 in the evening.
Age: 2.0
Sex: M
Vaccine: HEPA
Symptoms: Inappropriate schedule of drug administration
Clinical narrative: Patient received Hep A vaccine #2 only 28 days after the first dose.
Age: 31.0
Sex: M
Vaccine: SMALL
Symptoms: Axillary pain, Dizziness, Fatigue, Swelling
Clinical narrative: Pt developed fatigue, lightheadedness, and painful swelling in R axilla 4-5 days after vaccine administration in R upper arm. Pt seen today in clinic w/ same complaints. Says symptoms have been stable over last 2-3 days. Denies LOC, HA, f/c, SOB, chest pain, n/v.
Age: 23.0
Sex: F
Vaccine: SMALL
Symptoms: Arthropod bite, Blister, Cellulitis, Induration, Polymerase chain reaction
Clinical narrative: On 3/25/2007, six days after contact with a soldier who had been vaccinated for smallpox sometime during the week of 3/12/2007, patient noted area of induration, swelling and blisters on inner thigh. Three days prior to blisters, patient noted a bruised sensation in the same area. First treatment was for presumed cellulitis secondary to insect bite on 3/29/07 (Augmentin BID and NSAIDS); next treatment on 3/30/07 was for suspected vaccinia (different provider) with Augmentin continued, Doxycycline added (at this stage there was single approximately 2 cm tender, pruritic, erythematous ulceration that was deep with grey whiteish pustule in center that was lanced and packed. Patient was seen in follow-up (by third provider) on 4/3/07 when ulceration was only about 6 mm in size with no associated erythema: antibiotics discontinued and patient released back to work.
Age: 23.0
Sex: F
Vaccine: SMALL
Symptoms: Rash erythematous, Rash pruritic, Rash pustular, Skin ulcer, Swelling
Clinical narrative: On 3/25/2007, six days after contact with a soldier who had been vaccinated for smallpox sometime during the week of 3/12/2007, patient noted area of induration, swelling and blisters on inner thigh. Three days prior to blisters, patient noted a bruised sensation in the same area. First treatment was for presumed cellulitis secondary to insect bite on 3/29/07 (Augmentin BID and NSAIDS); next treatment on 3/30/07 was for suspected vaccinia (different provider) with Augmentin continued, Doxycycline added (at this stage there was single approximately 2 cm tender, pruritic, erythematous ulceration that was deep with grey whiteish pustule in center that was lanced and packed. Patient was seen in follow-up (by third provider) on 4/3/07 when ulceration was only about 6 mm in size with no associated erythema: antibiotics discontinued and patient released back to work.
Age: 23.0
Sex: F
Vaccine: SMALL
Symptoms: Tenderness, Vaccinia
Clinical narrative: On 3/25/2007, six days after contact with a soldier who had been vaccinated for smallpox sometime during the week of 3/12/2007, patient noted area of induration, swelling and blisters on inner thigh. Three days prior to blisters, patient noted a bruised sensation in the same area. First treatment was for presumed cellulitis secondary to insect bite on 3/29/07 (Augmentin BID and NSAIDS); next treatment on 3/30/07 was for suspected vaccinia (different provider) with Augmentin continued, Doxycycline added (at this stage there was single approximately 2 cm tender, pruritic, erythematous ulceration that was deep with grey whiteish pustule in center that was lanced and packed. Patient was seen in follow-up (by third provider) on 4/3/07 when ulceration was only about 6 mm in size with no associated erythema: antibiotics discontinued and patient released back to work.
Age: 11.0
Sex: F
Vaccine: FLUX, MNQ, TDAP, VARCEL
Symptoms: Pruritus, Rash erythematous, Urticaria
Clinical narrative: Hives occured 4 days after vaccine administration- itchy red bumps.
Age: 58.0
Sex: F
Vaccine: TDAP
Symptoms: Auricular swelling, Rash, Swelling face
Clinical narrative: Swelling started 4/6/07 with swelling of the earlobe on one rt side of face.Swelling moved from front of ear to ear lobe straight across cheek bone dropped in jowls/ neck. Rash in temple area.
Age: 60.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site erythema, Injection site warmth, Musculoskeletal pain, Paraesthesia
Clinical narrative: CLIENT STATES THAT AFTER FLU INJ SHE BEGAN W/ C/O SHOULDER PAIN, BEING 'PARALYZED' AND 'NO FEELING ' IN l SHOULDER.  ALSO REPORTS THAT INJ SITE WAS RED AND WARM.  SAW PMD ON 11/01/06 AND REFERRED TO NEURO BUT ALL TESTING HAS BEEN NEGATIVE.  CONTINUES W/ C/O DIZZINESS AND SORENESS
Age: 45.0
Sex: F
Vaccine: TDAP
Symptoms: Myalgia, Neck pain, Pain in extremity
Clinical narrative: Employee complained of pain in the trapezius muscle radiating up to neck in the arm vaccine given
Age: 0.16
Sex: M
Vaccine: RVX
Symptoms: Electrocardiogram, Erythema, Gaze palsy, Heart rate increased, Musculoskeletal stiffness
Clinical narrative: Pediarix administered L vastus laeralis, 0.5cc IM per protocol. Pt became red and stiff, eyes rolled back in head. Episode lasted approximately one minute. Then patien was pale for approximately 5 mins. Dr. attending. O2 sat 85 % on room air. O2 via pedi mask, 3L applied. EMS activated. O2 sat upon paramedic arrival 99%. Pt to ER via ambulance. Breathing and conscious upon departure. Carried by mother to ambulance. Mother states child subject to similar episodes when changing diapers or not picked up quickly. Mother states this episode "stronger". Evaluation at Hospital.
Age: 0.16
Sex: M
Vaccine: RVX
Symptoms: Oxygen saturation, Oxygen saturation decreased, Oxygen saturation normal, Oxygen supplementation, Pallor
Clinical narrative: Pediarix administered L vastus laeralis, 0.5cc IM per protocol. Pt became red and stiff, eyes rolled back in head. Episode lasted approximately one minute. Then patien was pale for approximately 5 mins. Dr. attending. O2 sat 85 % on room air. O2 via pedi mask, 3L applied. EMS activated. O2 sat upon paramedic arrival 99%. Pt to ER via ambulance. Breathing and conscious upon departure. Carried by mother to ambulance. Mother states child subject to similar episodes when changing diapers or not picked up quickly. Mother states this episode "stronger". Evaluation at Hospital.
Age: 16.0
Sex: M
Vaccine: MMR, TDAP
Symptoms: Chills, Nausea, Pyrexia, Vomiting
Clinical narrative: Woke up 12 hours later with fever (102.3), shivering, nausea and vomiting x 2.
Age: 16.0
Sex: F
Vaccine: MNQ, MNQ
Symptoms: Asthenia, Blood test normal, Computerised tomogram head, Computerised tomogram normal, Headache
Clinical narrative: 03/30/07--Client awoke with moderate HA, increasing in intensity over 8 days. 04/05/07--Client TIA S/S--weakness in knees, inability to control limbs, tingling of RT side including leg,arm, face, speech garbled, repeated short series of words, some conversation was not understandable or correct in nature for 45-60 minutes. When speech cleared, it was deliberate speech as if to force mouth to obey.  04/09/07 S/S seem to be resolving.  Menactra verified and updated in VAERS.  04/19/2007 MR received for 2 day hospitalization (04/5-6/2007 for c/o of 7 day hx. of headache with resolution that day, but onset of expressive apahasia, bilateral arm weakness, and facial numbness. Upon PE there are no apparent deficits except for significant inability to express thoughts, formulate thoughts or express and state words.  Symptoms resolved approx. 5 minutes after exam. Assessment:  Transient expressive aphasia with neurological deficits s/p meningitis vaccine.  Possible variant of Guillain-Barre. 06/04/2007 Per CDC: Please add the info below to the NURFU for VAERS # 275804: "VAERS 275804 is NOT GBS according to person from CISA."
Age: 16.0
Sex: F
Vaccine: MNQ, MNQ
Symptoms: Loss of control of legs, Paraesthesia, Repetitive speech, Speech disorder, Transient ischaemic attack
Clinical narrative: 03/30/07--Client awoke with moderate HA, increasing in intensity over 8 days. 04/05/07--Client TIA S/S--weakness in knees, inability to control limbs, tingling of RT side including leg,arm, face, speech garbled, repeated short series of words, some conversation was not understandable or correct in nature for 45-60 minutes. When speech cleared, it was deliberate speech as if to force mouth to obey.  04/09/07 S/S seem to be resolving.  Menactra verified and updated in VAERS.  04/19/2007 MR received for 2 day hospitalization (04/5-6/2007 for c/o of 7 day hx. of headache with resolution that day, but onset of expressive apahasia, bilateral arm weakness, and facial numbness. Upon PE there are no apparent deficits except for significant inability to express thoughts, formulate thoughts or express and state words.  Symptoms resolved approx. 5 minutes after exam. Assessment:  Transient expressive aphasia with neurological deficits s/p meningitis vaccine.  Possible variant of Guillain-Barre. 06/04/2007 Per CDC: Please add the info below to the NURFU for VAERS # 275804: "VAERS 275804 is NOT GBS according to person from CISA."
Age: 16.0
Sex: F
Vaccine: MNQ, MNQ
Symptoms: Aphasia, Dyskinesia, Headache, Hypoaesthesia facial, Muscular weakness
Clinical narrative: 03/30/07--Client awoke with moderate HA, increasing in intensity over 8 days. 04/05/07--Client TIA S/S--weakness in knees, inability to control limbs, tingling of RT side including leg,arm, face, speech garbled, repeated short series of words, some conversation was not understandable or correct in nature for 45-60 minutes. When speech cleared, it was deliberate speech as if to force mouth to obey.  04/09/07 S/S seem to be resolving.  Menactra verified and updated in VAERS.  04/19/2007 MR received for 2 day hospitalization (04/5-6/2007 for c/o of 7 day hx. of headache with resolution that day, but onset of expressive apahasia, bilateral arm weakness, and facial numbness. Upon PE there are no apparent deficits except for significant inability to express thoughts, formulate thoughts or express and state words.  Symptoms resolved approx. 5 minutes after exam. Assessment:  Transient expressive aphasia with neurological deficits s/p meningitis vaccine.  Possible variant of Guillain-Barre. 06/04/2007 Per CDC: Please add the info below to the NURFU for VAERS # 275804: "VAERS 275804 is NOT GBS according to person from CISA."
Age: 16.0
Sex: F
Vaccine: MNQ, MNQ
Symptoms: Paraesthesia
Clinical narrative: 03/30/07--Client awoke with moderate HA, increasing in intensity over 8 days. 04/05/07--Client TIA S/S--weakness in knees, inability to control limbs, tingling of RT side including leg,arm, face, speech garbled, repeated short series of words, some conversation was not understandable or correct in nature for 45-60 minutes. When speech cleared, it was deliberate speech as if to force mouth to obey.  04/09/07 S/S seem to be resolving.  Menactra verified and updated in VAERS.  04/19/2007 MR received for 2 day hospitalization (04/5-6/2007 for c/o of 7 day hx. of headache with resolution that day, but onset of expressive apahasia, bilateral arm weakness, and facial numbness. Upon PE there are no apparent deficits except for significant inability to express thoughts, formulate thoughts or express and state words.  Symptoms resolved approx. 5 minutes after exam. Assessment:  Transient expressive aphasia with neurological deficits s/p meningitis vaccine.  Possible variant of Guillain-Barre. 06/04/2007 Per CDC: Please add the info below to the NURFU for VAERS # 275804: "VAERS 275804 is NOT GBS according to person from CISA."
Age: 26.0
Sex: F
Vaccine: HPV4
Symptoms: Dizziness, Head injury, Nausea, Vertigo
Clinical narrative: Patient reported "dizziness", "room spinning", some nausea symptoms beginning 11 hours after administration of vaccine. Dizziness woke patient during the night due to severity. Symptoms were continuing at time of discussion with patient at approximately 56 hours after administration. Symptoms worsen with position change, movement.  Patient also reports striking top of head in a swimming pool approximately 4 hours after receiving vaccination.  Patient will see MD if symptoms do not improve.
Age: 34.0
Sex: M
Vaccine: SMALL
Symptoms: Erythema multiforme
Clinical narrative: erythema multiforme minor from small pox vaccine